Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused ...

Belite Bio (BLTE) announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...

Belite Bio, Inc. has announced a securities purchase agreement with a new healthcare investor to sell 258,309 American Depositary Shares (ADSs) and warrants at a price of $58.07 per ADS ...

After hours: February 7 at 4:01:31 PM EST Loading Chart for BLTE ...

JPMorgan Chase & Co. boosted its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 7,122.7% in the 3rd ...

Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous target of $57.00, while reiterating a Buy rating on the stock. The decision ...